Exelixis Net Income Over Time
| EXEL Stock | USD 42.37 0.28 0.66% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Exelixis Performance and Exelixis Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. Projected growth potential of Exelixis fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Exelixis assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.725 | Earnings Share 2.36 | Revenue Per Share | Quarterly Revenue Growth 0.108 | Return On Assets |
Investors evaluate Exelixis using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Exelixis' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Exelixis' market price to deviate significantly from intrinsic value.
It's important to distinguish between Exelixis' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Exelixis should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Exelixis' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Exelixis and related stocks such as Biomarin Pharmaceutical, Moderna, and Revolution Medicines Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMRN | (12.3 M) | (53.8 M) | (114.3 M) | (176.4 M) | (134 M) | (171.8 M) | (630.2 M) | (117 M) | (77.2 M) | (23.8 M) | 854 M | (64.1 M) | 141.6 M | 167.6 M | 426.9 M | 26.8 M | 28.1 M |
| MRNA | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (1.1 M) | (216.2 M) | (255.9 M) | (384.7 M) | (514 M) | (747.1 M) | 12.2 B | 8.4 B | (4.7 B) | (3.6 B) | (4.1 B) | (3.9 B) |
| RVMD | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (41.8 M) | (47.7 M) | (108.2 M) | (187.1 M) | (248.7 M) | (436.4 M) | (600.1 M) | (540.1 M) | (513.1 M) |
| TECH | 400 K | 112.3 M | 112.6 M | 110.9 M | 107.7 M | 104.5 M | 77.3 M | 125.3 M | 96.1 M | 229.3 M | 140.4 M | 272.1 M | 285.3 M | 168.1 M | 73.4 M | 84.4 M | 87.1 M |
| HALO | (39.7 K) | (19.8 M) | (53.6 M) | (83.5 M) | (68.4 M) | (32.2 M) | (103 M) | 63 M | (80.3 M) | (72.2 M) | 129.1 M | 402.7 M | 202.1 M | 281.6 M | 444.1 M | 510.7 M | 536.2 M |
| MDGL | (381 K) | (47.4 M) | (62.8 M) | (90.2 M) | (86.2 M) | (6.8 M) | (26.4 M) | (31.2 M) | (32.8 M) | (72.8 M) | (197.4 M) | (241.1 M) | (295.4 M) | (373.6 M) | (465.9 M) | (419.3 M) | (398.3 M) |
| RNA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (24.7 M) | (44 M) | (117.4 M) | (169.1 M) | (212.2 M) | (322.3 M) | (290.1 M) | (275.6 M) |
| BBIO | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (130.7 M) | (260.4 M) | (448.7 M) | (562.5 M) | (481.2 M) | (643.2 M) | (535.8 M) | (482.2 M) | (506.3 M) |
| CAI | (2.6 M) | 50.2 M | 63.5 M | 63.9 M | 60.3 M | 26.8 M | 6 M | 72.1 M | 78.6 M | 31 M | 27.7 M | (320.8 M) | (320.8 M) | (341.4 M) | (281.9 M) | (253.7 M) | (241 M) |
| ALGN | (15.4 M) | 66.7 M | 58.7 M | 64.3 M | 145.8 M | 144 M | 189.7 M | 231.4 M | 400.2 M | 442.8 M | 1.8 B | 772 M | 361.6 M | 445.1 M | 421.4 M | 484.6 M | 508.8 M |
Exelixis and related stocks such as Biomarin Pharmaceutical, Moderna, and Revolution Medicines Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Exelixis financial statement analysis. It represents the amount of money remaining after all of Exelixis operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Exelixis | EXEL |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1851 Harbor Bay |
| Exchange | NASDAQ Exchange |
USD 42.37
Check out Exelixis Performance and Exelixis Correlation. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Exelixis technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.